Optimization of 131I activity value required for thyroid remnants and metastatic lesions ablation in children with differentiated thyroid cancer

被引:0
|
作者
Kozak, OV [1 ]
Shishkina, VV [1 ]
Korchinskaya, OL [1 ]
Sagan, DL [1 ]
Dzhuza, DA [1 ]
Trocevskiy, VV [1 ]
机构
[1] Ukraine Acad Med Sci, Inst Oncol, UA-03022 Kiev, Ukraine
关键词
thyroid cancer in children; I-131;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
66 children with differentiated thyroid cancer have been treated with I'll after thyroidectomy. Activities administered amounted from 370 to 5600 MBq. Patients were divided into three groups according to scintigraphy data: Group 1-with thyroid remnants only (25 patients), Group 2-with metastatic lesions in lymph nodes (15 patients), Group 3-with metastatic lesions in lungs (26 patients). The aim of the study was to evaluate parameters of radioiodine accumulation and excretion in remnants during radioiodine treatment in children after thyroidectomy, to determine the influence of I'll activity value on the result of the first course of radioiodine treatment. The fraction (f) of patients with thyroid remnants ablation after first course of the treatment within each specified activity range has been calculated and plotted against each interval of I-131 activity. In Group 3 number of courses required for total ablation of thyroid tissue was evaluated as a function of activities administered. In Group 1 f has a constant value (about 0.55) within the range of 1000-2500 MBq followed by the abrupt increase (up to 1) at 2500 MBq remaining at this plateau value with further increase of activity. In Group 3 number of courses of radioiodine treatment largely depends first activity value, namely the greater is first activity value the less is number of courses required for total ablation of remnants and metastatic lesions. The activity 2500 MBq could be considered as an optimal value for thyroid remnants ablation after first course of radioiodine treatment in children without metastatic lesions accumulating radioiodine, while in groups with metastatic lesions, for minimizing number of courses, first activity should be not less then 4000 MBq.
引用
收藏
页码:221 / 224
页数:4
相关论文
共 50 条
  • [41] Dosimetry of 131I in remnant ablation and metastasis of differentiated thyroid cancer treated with high radioactivities and rhTSH
    Ramirez-Franco, Jorge
    Torres-Garcia, Eugenio
    Flores-Reyes, Mario
    Torres-Garcia, Gustavo
    Perez-Soto, Elvia
    RADIATION EFFECTS AND DEFECTS IN SOLIDS, 2024, 179 (9-10): : 1284 - 1294
  • [42] EFFECTS OF LEVOTHYROXINE ON BONE METABOLISM IN PATIENTS WITH DIFFERENTIATED THYROID CANCER AFTER OPERATION AND 131I ABLATION
    陈立波
    罗全勇
    余永利
    袁志斌
    陆汉魁
    朱瑞森
    章振林
    Medical Bulletin of Shanghai Jiaotong University, 2007, (02) : 95 - 99
  • [43] Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
    Wang, Chen
    Diao, Hongcui
    Ren, Ping
    Wang, Xufu
    Wang, Yangang
    Zhao, Wenjuan
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [44] Serum thyroglobulin in evaluating the response to 131I treatment in patients with distant metastatic differentiated thyroid cancer
    慕转转
    China Medical Abstracts (Internal Medicine), 2020, 37 (03) : 130 - 131
  • [45] Impact of 131I diagnostic activities on the biokinetics of thyroid remnants
    Lassmann, M
    Luster, M
    Hänscheid, H
    Reiners, C
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (04) : 619 - 625
  • [46] On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer
    Paolo Zanotti-Fregonara
    Elif Hindié
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 2264 - 2266
  • [47] Efficacy of Dosimetric Versus Empiric Prescribed Activity of 131I for Therapy of Differentiated Thyroid Cancer
    Klubo-Gwiezdzinska, Joanna
    Van Nostrand, Douglas
    Atkins, Frank
    Burman, Kenneth
    Jonklaas, Jacqueline
    Mete, Mihriye
    Wartofsky, Leonard
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (10): : 3217 - 3225
  • [48] Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I Theragnostics
    Avram, Anca M.
    Rosculet, Natalja
    Esfandiari, Nazanene H.
    Gauger, Paul G.
    Miller, Barbra S.
    Cohen, Mark
    Hughes, David T.
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (01) : 11 - 20
  • [49] On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer
    Zanotti-Fregonara, Paolo
    Hindie, Elif
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (12) : 2264 - 2266
  • [50] Evaluation of response to 131I treatment in children and adolescent with differentiated thyroid carcinoma
    Salvatori, M.
    Spitilli, M. G.
    Pizzoferro, M.
    Maussier, M. L.
    Perotti, G.
    Garganese, M. C.
    Giordano, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S342 - S343